Pharma giant Pfizer says its experimental cancer therapy ELREXFIO has delivered a major win in a pivotal late-stage trial, significantly delaying disease progression in patients with hard-to-treat multiple myeloma.
The Phase 3 MagnetisMM-5 study showed the drug, used alone, outperformed a widely used standard treatment regimen in patients whose cancer had returned or stopped responding to prior therapies.
The key measure—progression-free survival—improved by a statistically significant and clinically meaningful margin, according to the company.
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis, surpassing expectations set for the trial. Safety results were in line with what doctors have seen before, with no new concerns emerging.
The trial is still ongoing, with researchers continuing to track overall survival—a crucial benchmark that has not yet matured. Pfizer plans to present detailed findings at a future medical meeting and share the data with regulators worldwide.
Multiple myeloma, an aggressive and incurable blood cancer, remains a major global health burden. It is the second most common blood cancer.
“Effective intervention earlier in the course of disease represents a critical opportunity to improve outcomes for people living with multiple myeloma,” said Jeff Legos, Chief Oncology Officer, Pfizer.
“ELREXFIO has already helped address a significant unmet need in heavily pre-treated patients, delivering deep, durable, and clinically meaningful responses.
"The MagnetisMM-5 results reinforce our confidence in ELREXFIO’s potential to benefit patients earlier in their treatment journey and support our comprehensive strategy to evaluate ELREXFIO both as monotherapy and as part of combination approaches across multiple lines of therapy.”
ELREXFIO is already cleared for use in more than 35 countries, including the United States and the European Union, for patients who have undergone multiple prior treatments.
The MagnetisMM-5 trial is part of a broader development push targeting patients exposed to multiple drug classes, including another ongoing Phase 3 study examining the therapy in earlier treatment settings.
If longer-term results hold, ELREXFIO could shift how doctors treat multiple myeloma—moving a powerful option earlier in the disease, where it may have the greatest impact.
